MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy
暂无分享,去创建一个
Linda Moy | L. Moy | S. Adams | Rachel L Sabado | Maxwell Janosky | Crystal Cruz | Isabelita Vengco | Farah Hasan | Arthur Winer | Sylvia Adams | R. Sabado | C. Cruz | Maxwell Janosky | Arthur Winer | F. Hasan | I. Vengco | Isabelita Vengco
[1] D. Petrylak,et al. Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.
[2] S. Steinberg,et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] Molin Wang,et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Schneeweiss,et al. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial , 2013, Cancer Immunology, Immunotherapy.
[5] K. Knutson,et al. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.
[6] Yao-Tseng Chen,et al. Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.
[7] E. Mittendorf,et al. Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 , 2008, Clinical Cancer Research.
[8] S. Vogel,et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.
[9] E. Lee,et al. The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma , 2005, Cancer.
[10] D. Gabrilovich,et al. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect , 2010, Expert opinion on biological therapy.
[11] M. Cheever. Twelve immunotherapy drugs that could cure cancers. , 2008, Immunological reviews.
[12] D. Pardoll,et al. The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.
[13] M. Roederer,et al. T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.
[14] Keith L Black,et al. Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.
[15] Yixiang Wang,et al. Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo , 2009, The Journal of Immunology.
[16] M. Monden,et al. NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors , 2004, Cancer Research.
[17] S. Demaria,et al. Cross-Talk of Breast Cancer Cells with the Immune System , 2011 .
[18] I. Davis,et al. Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage , 2006, Clinical Cancer Research.
[19] M. Pfreundschuh,et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer , 2006, International journal of cancer.
[20] A. Simpson,et al. CT-X antigen expression in human breast cancer , 2009, Proceedings of the National Academy of Sciences.
[21] M. Gunduz. Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways , 2011 .
[22] D. Jäger,et al. NY‐ESO‐1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T‐cell and CD79a+ plasmacytic/B‐cell infiltration , 2007, International journal of cancer.
[23] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[24] S. Demaria,et al. Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer , 2012, Clinical Cancer Research.
[25] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Roden,et al. Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ , 2014, Clinical Cancer Research.
[27] W. Gillanders,et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.
[28] S. Adams,et al. Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1 , 2008, The Journal of Immunology.
[29] Yao-Tseng Chen,et al. CT7 (MAGE‐C1) antigen expression in normal and neoplastic tissues , 2002, International journal of cancer.
[30] M. Ladanyi,et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7 , 2001, International journal of cancer.
[31] L. O’Driscoll,et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer , 2008, Breast Cancer Research and Treatment.
[32] M. Mazumdar,et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. , 2007, Cancer immunity.
[33] V. Kosma,et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.
[34] E. Jaffee,et al. Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.
[35] C. Bokemeyer,et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming , 2008, Proceedings of the National Academy of Sciences.
[36] J. Gribben,et al. Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy , 2005, Clinical Cancer Research.
[37] Ian O Ellis,et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] P. Haaland,et al. Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. , 2007, Journal of immunology.
[39] K. Hess,et al. Effect of HER2 status on distant recurrence in early stage breast cancer , 2012, Breast Cancer Research and Treatment.
[40] M. Lichinitser,et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Goldhirsch,et al. Cancer-testis antigen expression in triple-negative breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[43] L. Terracciano,et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study , 2001, Virchows Archiv.
[44] K. Pantel,et al. MAGE-A gene expression pattern in primary breast cancer. , 2001, Cancer research.
[45] Yao-Tseng Chen,et al. Expression of MAGE‐antigens in normal tissues and cancer , 2000, International journal of cancer.
[46] A. Schneeweiss,et al. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study , 2009, Cancer Immunology, Immunotherapy.